Armida D'incecco
Teramo, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.
Journal: Journal for immunotherapy of cancer
Published: July 31, 2025
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Journal: Journal for immunotherapy of cancer
Published: December 29, 2024
MS4A15 gene expression as a prognostic marker for clinical outcomes in lung adenocarcinoma.
Journal: Translational lung cancer research
Published: July 18, 2024
Chest wall reconstruction in benign and malignant tumors with non-rigid materials: An overview.
Journal: Frontiers in surgery
Published: June 23, 2022
Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial.
Journal: Translational lung cancer research
Published: May 20, 2022
Multidisciplinary and real life data: practical management of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC).
Journal: Journal of thoracic disease
Published: February 12, 2022
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer.
Journal: Oncotarget
Published: April 25, 2018
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
Journal: The Lancet. Respiratory medicine
Published: January 11, 2018
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC).
Journal: Oncotarget
Published: November 28, 2017
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.
Journal: Cytokine & growth factor reviews
Published: July 10, 2017
The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer.
Journal: Science signaling
Published: January 18, 2017
microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 03, 2015
Last Updated: 09/26/2026